Evolution of treatment regimens in multiple myeloma: a social network analysis

Helen Mahony1, Athanasios Tsalatsanis1, Ambuj Kumar1

  • 1Department of Internal Medicine, Division of Evidence-Based Medicine & Health Outcomes Research, University of South Florida, Tampa, Florida, United States of America.

Plos One
|August 15, 2014
PubMed
Abstract

Insights

Randomized controlled trials in multiple myeloma are decentralized, with few direct comparisons between key treatments. This lack of connectivity reveals unexplored research, suggesting social network analysis can improve future trial design.

Area of Science:

  • Hematology
  • Clinical Trials
  • Network Science

Background:

  • Randomized controlled trials (RCTs) are crucial for evaluating new treatments.
  • The rationale for selecting treatments in RCTs is often not well-defined.
  • Understanding treatment selection patterns in multiple myeloma (MM) RCTs is important.

Purpose of the Study:

  • To analyze treatment selection patterns in multiple myeloma (MM) randomized controlled trials (RCTs).
  • To examine the network topology of treatment regimens within MM RCTs using social network analysis (SNA).

Main Methods:

  • A comprehensive search of Medline and conference abstracts was conducted for MM RCTs.
  • Data extracted included treatment regimens, publication year, funding, and patient enrollment.
  • Social network analysis (SNA) metrics were applied to evaluate network structure and centrality.

Main Results:

  • 135 RCTs with 36,869 patients were analyzed, revealing a low-density treatment network.
  • Low Network Betweenness indicated limited information exchange between treatments.
  • A maximum geodesic distance of 4 suggested limited direct comparisons, with many important regimens not yet compared in RCTs.

Conclusions:

  • Multiple myeloma research exhibits surprising decentralization and poor connectivity among research pathways.
  • Significant unexplored research exists due to the lack of direct treatment comparisons in RCTs.
  • Employing SNA before clinical trial design can enhance study planning and research efficiency.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
857
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
635